1226P Predicting benefit from maintenance durvalumab after first-line chemotherapy (1L CTx) in oesophagogastric adenocarcinoma (OGA) using a novel tumour microenvironment (TME) RNA-based assay. - Fong, C.Y.K.; Iyer, S.; Potts, L.; Peckitt, C.; Cromarty, S.; Saffery, C.; Kidd, S.; Rana, T.; Ausec, L.; Gregorc, A.; Pointing, D.; Gombert, M.; et al. (Annals of Oncology, 2022)